Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Grows By 95.2%

Vincerx Pharma, Inc. (NASDAQ:VINC - Get Free Report) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 863,700 shares, a growth of 95.2% from the February 29th total of 442,400 shares. Based on an average trading volume of 1,030,000 shares, the days-to-cover ratio is currently 0.8 days. Currently, 6.4% of the shares of the stock are short sold.

Vincerx Pharma Stock Performance

NASDAQ VINC traded down $1.00 on Thursday, reaching $5.06. The company's stock had a trading volume of 601,837 shares, compared to its average volume of 1,094,468. Vincerx Pharma has a twelve month low of $0.61 and a twelve month high of $9.37. The stock has a market cap of $108.18 million, a PE ratio of -2.39 and a beta of 1.03. The firm's 50 day moving average is $3.50 and its two-hundred day moving average is $1.82.

Institutional Investors Weigh In On Vincerx Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Rock Springs Capital Management LP lifted its holdings in Vincerx Pharma by 0.6% in the 1st quarter. Rock Springs Capital Management LP now owns 814,194 shares of the company's stock valued at $3,257,000 after acquiring an additional 4,999 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Vincerx Pharma by 21.3% during the 2nd quarter. Goldman Sachs Group Inc. now owns 36,126 shares of the company's stock worth $48,000 after buying an additional 6,334 shares during the period. Vanguard Group Inc. raised its holdings in Vincerx Pharma by 1.8% during the 1st quarter. Vanguard Group Inc. now owns 666,019 shares of the company's stock worth $2,664,000 after buying an additional 11,667 shares during the period. Rhumbline Advisers acquired a new stake in Vincerx Pharma during the 1st quarter worth about $53,000. Finally, Renaissance Technologies LLC raised its holdings in Vincerx Pharma by 7.7% during the 1st quarter. Renaissance Technologies LLC now owns 195,000 shares of the company's stock worth $203,000 after buying an additional 14,000 shares during the period. 44.02% of the stock is owned by institutional investors and hedge funds.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.